Axsome Therapeutics, Inc. (AXSM)

NASDAQ: AXSM · Real-Time Price · USD
93.24
+2.73 (3.02%)
Oct 2, 2024, 4:00 PM EDT - Market closed
3.02%
Market Cap 4.48B
Revenue (ttm) 291.49M
Net Income (ttm) -308.55M
Shares Out 48.00M
EPS (ttm) -6.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 444,799
Open 90.02
Previous Close 90.51
Day's Range 89.92 - 95.72
52-Week Range 55.02 - 98.40
Beta 1.25
Analysts Strong Buy
Price Target 124.57 (+33.6%)
Earnings Date Nov 4, 2024

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2015
Employees 545
Stock Exchange NASDAQ
Ticker Symbol AXSM
Full Company Profile

Financial Performance

In 2023, Axsome Therapeutics's revenue was $270.60 million, an increase of 440.80% compared to the previous year's $50.04 million. Losses were -$239.24 million, 27.8% more than in 2022.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is $124.57, which is an increase of 33.60% from the latest price.

Price Target
$124.57
(33.60% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste...

4 weeks ago - GlobeNewsWire

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...

6 weeks ago - GlobeNewsWire

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company's SG&A and R&D expenses significantly increased, leading to wider net losse...

2 months ago - Seeking Alpha

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick ...

2 months ago - Seeking Alpha

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024...

2 months ago - GlobeNewsWire

Axsome Therapeutics: Lots Of Moving Parts

Today, we circle back to mid-cap biopharma Axsome Therapeutics, which has multiple potential catalysts on the horizon. The company has two approved products on the market and the potential to have six...

2 months ago - Seeking Alpha

Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future

Needham initiated coverage on Axsome Therapeutics Inc AXSM, which focuses on central nervous disorders conditions, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibrom...

2 months ago - Benzinga

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervo...

4 months ago - GlobeNewsWire

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...

4 months ago - GlobeNewsWire

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and t...

4 months ago - Seeking Alpha

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system ...

4 months ago - GlobeNewsWire

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

Axsome Therapeutics develops treatments for CNS conditions, with two commercial products: Auvelity for major depressive disorders and Sunosi for sleep disorders. The company has a diverse pipeline tar...

5 months ago - Seeking Alpha

Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system ...

5 months ago - GlobeNewsWire

Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Conference Call May 6, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief Execut...

5 months ago - Seeking Alpha

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 202...

5 months ago - GlobeNewsWire

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system ...

5 months ago - GlobeNewsWire

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

AXS-05 in Alzheimer's disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting ef...

6 months ago - GlobeNewsWire

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste...

6 months ago - GlobeNewsWire

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste...

6 months ago - GlobeNewsWire

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by t...

6 months ago - GlobeNewsWire

Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial

Axsome Therapeutics said on Monday its therapy for a sleep disorder met the main goal of a late-stage study.

6 months ago - Reuters

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.0...

6 months ago - GlobeNewsWire

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste...

7 months ago - GlobeNewsWire

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste...

7 months ago - GlobeNewsWire

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system...

7 months ago - GlobeNewsWire